Stocks · News reference
JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascentage Pharma Stock Could More Than Double: Analyst
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Outperform rating.
Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46
Citigroup analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Buy rating and announces Price Target of $46.